Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco P Schena

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Transplantation|March 9, 2005
Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter studySergio Stefoni, Karsten Midtved, Edward Cole, et al.
Drug Metabolism and Pharmacokinetics|August 16, 2012
Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patientsMariadelfina Molinaro, Laurent R Chiarelli, Luigi Biancone, et al.
Transplantation|July 28, 2011
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trialJosefina Alberú, Michael D Pascoe, Josep M Campistol, et al.
The Journal of Experimental Medicine|September 5, 2002
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 25, 2004
Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology GroupGiovanni M Frascà, Andrea Onetti-Muda, Francesca Mari, et al.
Transplantation|November 30, 2005
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal functionGraeme Russ, Giuseppe Segoloni, Rainer Oberbauer, et al.
Biochimica Et Biophysica Acta|November 6, 2016
Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylationFederica Parodi, Roberta Carosio, Marco Ragusa, et al.
Transplantation|May 22, 2013
A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipientsStuart M Flechner, Alihan Gurkan, Anders Hartmann, et al.
Transplantation|January 22, 2009
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialFrancesco P Schena, Michael D Pascoe, Josefina Alberu, et al.
BMC Nephrology|December 7, 2005
The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex traitFrancesco P Schena, Giuseppina Cerullo, Diletta D Torres, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Transplantation|March 9, 2005
Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter studySergio Stefoni, Karsten Midtved, Edward Cole, et al.
Drug Metabolism and Pharmacokinetics|August 16, 2012
Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patientsMariadelfina Molinaro, Laurent R Chiarelli, Luigi Biancone, et al.
Transplantation|July 28, 2011
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trialJosefina Alberú, Michael D Pascoe, Josep M Campistol, et al.
The Journal of Experimental Medicine|September 5, 2002
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 25, 2004
Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology GroupGiovanni M Frascà, Andrea Onetti-Muda, Francesca Mari, et al.
Transplantation|November 30, 2005
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal functionGraeme Russ, Giuseppe Segoloni, Rainer Oberbauer, et al.
Biochimica Et Biophysica Acta|November 6, 2016
Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylationFederica Parodi, Roberta Carosio, Marco Ragusa, et al.
Transplantation|May 22, 2013
A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipientsStuart M Flechner, Alihan Gurkan, Anders Hartmann, et al.
Transplantation|January 22, 2009
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialFrancesco P Schena, Michael D Pascoe, Josefina Alberu, et al.
BMC Nephrology|December 7, 2005
The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex traitFrancesco P Schena, Giuseppina Cerullo, Diletta D Torres, et al.
Pageof 8